The Readout Loud

View Top 200 Chart

Back to Rankings Page

Business
**The Readout Loud**

STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.

Latest Episodes:

Episode 88: Dr. David Sable on an alarming genetic test & Jorge Conde on the perils of bio-Twitter Nov 14, 2019

Show notes

Do you trust Google with your health data? Is "Gattaca" an outdated reference? And what's it like to get dunked on?

Episode 87: Derek Lowe on China's new Alzheimer's drug, blockbuster fish oil, & STAT's birthday Nov 07, 2019

Show notes

Why hope for China's new Alzheimer's drug turned into skepticism ? Is three a crowd in CAR-T? And what's a Bionomy?

Episode 86: Drugs that don't work, wearables in the desert, & excess 'innovation' Oct 31, 2019

Show notes

When should a drug be pulled from shelves? How do you pronounce "HLTH?" And how does Ann Coulter decide what to tweet?

Episode 85: Every angle on Biogen's shocking Alzheimer's news Oct 24, 2019

Show notes

What exactly is Biogen doing? When is a press release worth $12 billion? And what should patients make of whiplashing news? We're devoting this entire episode to Biogen's stunning announcement that aducanumab, its once-discarded treatment for Alzheimer's disease, is getting a second life.

Episode 84: CRISPR with Netflix filmmakers, Pharma's future in China & where VC dollars come from Oct 17, 2019

Show notes

Should drug companies be free-speech advocates? Is your retirement dependent on CRISPR? And how useful is a glow-in-the-dark dog?

Episode 83: How biotech VC works w/ health care journalist Maggie Fox, Vioxx and synthetic biology Oct 10, 2019

Show notes

STAT's Matthew Herper joins us to dig into the history of the infamous pain drug Vioxx and a new effort to bring it back as a rare disease treatment. Then, we discuss how the synthetic biology industry is growing up and getting corporate. Finally, health care journalist Maggie Fox dials in to explain her deep dive on venture capital in biotech.

Episode 82: Drug shortages with Dr. Ben Davies, congressional paralysis & biotech's foul mood Oct 03, 2019

Show notes

Does impeachment have a pharma angle? Who's to blame for drug shortages? And why is Wall Street down on biotech?

Episode 81: Vaping upheaval, DNA test dynamics, & the future of genome editing Sep 26, 2019

Show notes

What do we talk about when we talk about "vape"? Are there limits to business of DNA testing? And how hard is it to get yourself CRISPR'd? STAT's Megan Thielking joins the gang to break down a major week of news in the world of vaping and STAT's Sharon Begley relates the story of a desperate patient seeking off-the-books genome editing and its implications for the future of medical research.

Episode 80: Unicorn growth spurts, Amgen's future, & mice on Twitter Sep 19, 2019

Show notes

Who puts horns on unicorns? How do graying drug companies find green ideas? And what would mice tweet?

Episode 79: Pelosi's drug pricing plan, Moderna's mRNA drug factories, and a DIY disease cure Sep 12, 2019

Show notes

House Speaker Nancy Pelosi’s drug pricing plan is aggressive, but is it viable? Can Moderna turn cells into tiny drug-making factories? What’s it like to cure your own rare disease?

Our TOPPODCAST Picks

Follow Us

Stay Connected

Related Podcasts

Links

Stay Connected